Q-omics provides the consensus-scored VDAC2P2 profile across patient tissues and cancer cell-line models. VDAC2P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, VDAC2P2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, VDAC2P2 RNA expression shows 14,285 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KIRC, and LSCC as cancer lineages where VDAC2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VDAC2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VDAC2P2 survival associations across molecular data types. VDAC2P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VDAC2P2 RNA expression–survival associations across cancer types. High VDAC2P2 expression shows unfavorable associations in UVM, COAD, ACC and LUSC, but favorable associations in UCS and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify UCS as the clearest survival context for VDAC2P2 RNA expression.
This table summarizes VDAC2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VDAC2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VDAC2P2 shows lower tumor expression in BRCA, THCA, LIHC and COAD and higher tumor expression in KIRC. The KIRC box plot shows higher VDAC2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p < 0.001).
This table shows molecular features associated with VDAC2P2 in patient tissues and cancer cell lines. In patient samples, VDAC2P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
